Lyme Disease Diagnostic Workup
For patients with erythema migrans (EM) in an endemic area, diagnose clinically and treat immediately without laboratory testing; for all other presentations, use two-tiered serologic testing (EIA/IFA followed by Western blot) only when there is objective evidence of disseminated disease and appropriate epidemiologic exposure. 1
Clinical Diagnosis Without Laboratory Testing
Erythema migrans is the only manifestation that should be diagnosed and treated without serologic confirmation. 1, 2
- The rash must be a gradually expanding annular lesion >5 cm in diameter, documented by an experienced clinician in a patient with plausible tick exposure in an endemic area 1, 2
- Approximately 70-80% of Lyme disease patients present with EM 1
- Laboratory testing is unnecessary and may be misleading during early infection due to the antibody window period 1
Two-Tiered Serologic Testing Protocol
When laboratory testing is indicated, always use the complete two-tiered approach: first-tier EIA or IFA, followed by Western blot only if the first test is positive or equivocal. 1, 3
First-Tier Testing
- Order enzyme-linked immunoassay (EIA/ELISA) or immunofluorescence assay (IFA) as the initial screening test 1
- If negative and symptoms are present for <4 weeks, consider repeat testing in 2-4 weeks if clinical suspicion remains high 1
Second-Tier Western Blot Interpretation
- For disease duration <4 weeks: Interpret both IgM and IgG Western blots 3, 4
- For disease duration >4 weeks: Only interpret IgG Western blot; disregard IgM results due to high false-positive rates 3, 4
Test Performance Characteristics
- Sensitivity during early localized disease: 30-40% (due to antibody window period) 1
- Sensitivity for disseminated disease: 70-100% 1
- Specificity: >95% when two-tiered testing is performed correctly 1
Indications for Laboratory Testing
Test only when there are objective clinical findings of disseminated disease with appropriate epidemiologic exposure. 5, 1
Strong Indications (Test These Patients)
- Neurologic manifestations: Lymphocytic meningitis, cranial neuropathy (especially facial palsy), radiculoneuritis 5, 2, 3
- Cardiac manifestations: Acute myocarditis/pericarditis with dyspnea, palpitations, chest pain, syncope, or conduction abnormalities (PR >300 ms) in endemic areas 5, 3
- Articular manifestations: Intermittent swelling and pain of large joints, especially the knee 5, 2
- Multiple EM lesions (though single EM should be diagnosed clinically) 2
Do NOT Test These Patients
- Nonspecific symptoms without objective findings: Fatigue, myalgias, headache, paresthesias alone 5, 6, 3
- Psychiatric illness 5
- Chronic cardiomyopathy of unknown cause 5
- Typical presentations of ALS, MS, Parkinson's disease, dementia, or new-onset seizures 5, 3
- Nonspecific MRI white matter abnormalities without other clinical support 5
- Patients without tick exposure or travel to endemic areas 3, 4
Pre-Test Probability Assessment
Pre-test probability determines whether testing is appropriate and how to interpret results. 3, 4
High Pre-Test Probability
- Endemic area exposure (Northeast, Upper Midwest US) during tick season 1, 2
- Objective clinical findings consistent with disseminated Lyme disease 3, 4
- Recent tick bite or outdoor exposure in endemic region 3
Low Pre-Test Probability
- Non-endemic area without travel history 3
- No tick exposure 3
- Chronic symptoms lasting months without objective findings 3
- In non-endemic areas, positive predictive value of IgM is only ~10% (90% false-positives) 3
- Only 0.7% of patients with arthritis/neuropathy in low-incidence regions actually have Lyme disease 3
Additional Testing for Specific Manifestations
Neuroborreliosis
- CSF analysis with cell count, differential, protein 3
- CSF Lyme antibody index with concurrent serum sample for comparison 3
- Serum two-tiered testing 5
Lyme Carditis
- ECG for all patients with dyspnea, palpitations, chest pain, syncope, or lightheadedness 5
- Continuous cardiac monitoring for PR >300 ms or other arrhythmias 5
- Consider troponin and evaluation for pericardial effusion 5
Lyme Arthritis
- Serum antibody testing (preferred over PCR or culture) 5
- If seropositive but diagnosis uncertain, synovial fluid or tissue PCR 5
Critical Testing Pitfalls to Avoid
Never use unvalidated test methods or order testing in inappropriate clinical scenarios. 6, 1
- Do not order: Urine antigen tests, blood microscopy for Borrelia, CD57 testing 6, 3
- Do not test: Asymptomatic patients or those at tick bite presentation 3
- Do not interpret: Western blot without a positive first-tier test 3
- Do not diagnose: Based on 41 kDa band alone (present in ~43% of healthy controls) 3
- Do not retest: After treatment completion, as antibodies persist for months to years 3
- Do not screen: Patients with low pre-test probability, as false-positives will outnumber true cases 5, 3
Laboratory Selection
Use only well-qualified laboratories that employ FDA-cleared, validated testing methods with CDC-recommended interpretive criteria. 6, 1
- Ensure the laboratory follows standard two-tiered protocols 1, 3
- Verify proper Western blot band interpretation criteria 3
- Avoid laboratories offering non-standard or unvalidated assays 6
Initial Management Considerations
When to Treat Without Waiting for Test Results
- Typical EM in endemic area during appropriate season 2, 7
- High clinical suspicion for early disseminated disease with appropriate exposure 7
Antibiotic Selection Based on Manifestations
- Early localized disease (EM): Doxycycline 100 mg PO twice daily for 10-14 days 7, 8
- Early disseminated disease: 14-21 days of oral antibiotics 7
- Lyme arthritis: 28 days of oral antibiotics 5, 7
- CNS involvement: IV antibiotics 5, 7
- Lyme carditis (outpatient): Oral antibiotics; (hospitalized) initial IV ceftriaxone until improvement, then oral completion for total 14-21 days 5, 7
Co-infection Evaluation
- Consider testing for Babesia, Anaplasma, and Ehrlichia in patients with confirmed Lyme disease from endemic areas 3